BASEL, Switzerland, Nov. 22 /PRNewswire/ - Neuro-Biotech Corp. (PINKSHEET: MRES) (OTCQB: MRES) publishes answers to the most frequently asked questions.

The topic commonly asked about is in regards to Company's statements that no further R&D needs to be carried out on the 16 products that have been licensed. This technical platform was bought from a university following 20 years of research for the sum of $3 million. A total of $5 million was spent by the end of 2000 and subsequently, in the last 10 years research and development has yielded 16 products that are ready for production.

Neuro-Biotech's first blood test, SymPath has been the subject of more than 5,000 clinical tests and 75,000 units were sold before its voluntary withdrawal from the market. The SymPath is currently the only blood test on the planet which can successfully measure on a scale, recognized by the World Health Organization, (similar to the scale that is used to measure cholesterol) the mental state of a patient and by analogy the physical consequences, thus allowing physicians to carry out a more precise diagnosis. It should also be mentioned that the eighth blood test of our portfolio NeuroChAT is currently the only blood test allowing an early diagnosis of Alzheimer's Disease.

The Company has stated in its financials such as its 10-Q, that it does not have any employees because everyone works on a contractual basis, and the original agreements are with the two hedge funds who are financing the entire operation. This situation should change in the next few months with the set up and installation of the laboratory.

At the time of the acquisition of the licenses, the Company immediately created a deficit of more than $50 million by depreciating the value of those. In order to answer this recurring issue, the board of directors made this decision to avoid an over evaluation of the Company before it starts generating significant revenues. An independent third party evaluation by a specialized biotech firm is planned by management to assess the Company's assets and make a subsequent move onto a more important exchange. The evaluation by an independent firm specialized in biotech of the Company's assets will be planned when the direction will decide that the Company is in a position to upgrade to a more important exchange.

The Company would also like to point out that for its market penetration plans, Neuro-Biotech is also using the conclusions of a report ordered to the firm Ernst & Young (Toronto) concerning the potential market of its products.

The negotiations with the Spaniards are moving forward and the Company is preparing for two tours in Spain for 2011 with a group of representatives. Both tours will be separate and completely independent as one will be of scientific content while the other one will be focused on the commercial aspects. These tours will probably extend throughout Europe since the Company recently received similar proposals from Germany.

Finally, the Company foresees the receipt of the private placement of $2 million as well as full payment of the debt owed to third parties before the end of this year.

For more information and to view the documents describing the key elements mentioned above, we invite you visit the corporate website at www.neuro-biotechcorp.com

SOURCE Neuro-Biotech Corp.